Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomized, controlled, open-label, adaptive platform trial
Azithromycin, an antibiotic with potential antiviral and anti-inflammatory properties, has been used to treat COVID-19. Evidence from community randomized trials is lacking. The trial had two coprimary endpoints measured within 28 days from randomization. Inappropriate use of antibiotics leads to increased antimicrobial resistance. There is evidence that azithromycin use increased during the pandemic in the UK.